FDA
Rybelsus to be rebranded as Ozempic pill
Novo Nordisk announced that FDA-approved oral semaglutide tablets will be rebranded as Ozempic Pill, aligning the oral formulation with the well-known injectable Ozempic brand. The tablets—1.5 mg, 4 mg, and 9 mg—contain the same semaglutide molecule and are approved for adults with T2DM to improve glycemic control and reduce major adverse cardiovascular events in high‑risk patients.
The rebranding is intended to clarify treatment options by bringing both oral and injectable semaglutide under a single, recognizable name. The oral formulation maintains comparable efficacy and safety to earlier oral semaglutide doses through enhanced bioavailability. Novo Nordisk plans a U.S. launch in Q2 2026 and advises patients to continue current therapy until then. A supplemental application for a 25‑mg tablet is also currently under FDA review.
Sources:
Rybelsus (semaglutide) Ozempic (semaglutide) tablets [package insert]. Novo Nordisk. https://www.novo-pi.com/ozempictablets.pdf Revised January 2026. Accessed February 5, 2026.
(2026, February 4). Novo Nordisk. Novo Nordisk introduces Ozempic® Pill; Available in the US Q2 2026 [News release]. https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916488